Annals of the American Thoracic Society · 2024 · 23 citations · 40 references
MedicineInternal MedicineOutcomes ResearchSleep MedicineSurvival AnalysisContinuous Positive Airway PressurePositive Airway Pressure TherapySleep HealthSleep-disordered BreathingSleep-related Breathing DisordersSubgroup Effectiveness AnalysisApnea-hypopnea Index ReductionDifferential Treatment ResponseGroup SubgroupsHeterogeneous Treatment Effect EstimationObstructive Sleep Apnea TherapyObstructive Sleep Apnea TreatmentRecursive PartitioningSleep Apnea Prevention
Abstract Rationale Randomized controlled trials of continuous positive airway pressure (CPAP) therapy for cardiovascular disease (CVD) prevention among patients with obstructive sleep apnea (OSA) have been largely neutral. However, given that OSA is a heterogeneous disease, there may be unidentified subgroups demonstrating differential treatment effects. Objectives We sought to apply a novel data-drive approach to identify nonsleepy OSA subgroups with heterogeneous effects of CPAP on CVD outcomes within the Impact of Sleep Apnea Syndrome in the Evolution of Acute Coronary Syndrome (ISAACC) study. Methods Participants were randomly partitioned into two datasets. One for training (70%) our machine-learning model and a second (30%) for validation of significant findings. Model-based recursive partitioning was applied to identify subgroups with heterogeneous treatment effects. Survival analysis was conducted to compare treatment (CPAP vs. usual care [UC]) outcomes within subgroups. Results A total of 1,224 nonsleepy OSA participants were included. Of 55 features entered into our model, only two appeared in the final model (i.e., average OSA event duration and hypercholesterolemia). Among participants at or below the model-derived average event duration threshold (19.5 s), CPAP was protective for a composite of CVD events (training hazard ratio [HR], 0.46; P = 0.002). For those with longer event duration (>19.5 s), an additional split occurred by hypercholesterolemia status. Among participants with longer event duration and hypercholesterolemia, CPAP resulted in more CVD events compared with UC (training HR, 2.24; P = 0.011). The point estimate for this harmful signal was also replicated in the testing dataset (HR, 1.83; P = 0.118). Conclusions We discovered subgroups of nonsleepy OSA participants within the ISAACC study with heterogeneous effects of CPAP. Among the training dataset, those with longer OSA event duration and hypercholesterolemia had nearly 2.5 times more CVD events with CPAP compared with UC, whereas those with shorter OSA event duration had roughly half the rate of CVD events if randomized to CPAP.
40
Leo Breiman · Machine Learning · 2001 · 126.2K citations · Full text
Theo Vos, Stephen S Lim, Cristiana Abbafati et al. · The Lancet · 2020 · 19.2K citations · Full text
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Murray W. Johns · SLEEP · 1991 · 17.2K citations · Full text
Medicine, Neurology, Psychometrics +16
General Cardiovascular Risk Profile for Use in Primary Care
Ralph B. D’Agostino, Ramachandran S. Vasan, Michael Pencina et al. · Circulation · 2008 · 7.5K citations · Full text
Medicine, Cardiology, Risk Analysis +16